Dubai – Sharikat Mubasher: Mubadala Capital Ventures joined a $30 million investment in Tahoe Therapeutics, supporting the US-based biotech’s mission to advance precision medicine through large-scale single-cell datasets.
The funding, led by Amplify Partners, will enable Tahoe to generate one billion single-cell datapoints, mapping one million drug-patient interactions to accelerate the discovery of cancer treatments and other targeted therapies, as per a recent press release.
Mubadala joins a group of investors including Databricks Ventures, Wing Venture Capital, General Catalyst, Civilization Ventures, Conviction, and AIX Ventures.
Tahoe plans to grant a single strategic partner — from either the pharmaceutical or AI sectors — access to the dataset, aiming to develop the first medicines powered by “virtual cell models.” The company’s work builds on its Tahoe-100M dataset, which has been downloaded nearly 100,000 times since its release and has already contributed to identifying promising new therapeutic candidates.
